AstraZeneca announced that it has entered into a collaboration with Netherlands-based QIAGEN to develop a non-invasive diagnostic test to identify non-small cell lung cancer (NSCLC) patients who are suitable for treatment with IRESSA.

The average large cap score is 61.28, below the four week moving average of 64.18. The average large cap is trading -9.6% below its 52 week high, 4.52% above its 200 dma, has 3.94 days to cover held short, and is expected to generate EPS growth of 14% next year.